Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Neoplasm Metastasis 5Biliary Tract Neoplasms 4Stomach Neoplasms 3Neoplasms 3Esophageal Squamous Cell Carcinoma 3Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Plaque, Atherosclerotic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Overall Survival 1Osteosarcoma 1NSCLC 1Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

Doxorubicin 19Radiotherapy 10Ifosfamide 10apatinib 9anlotinib 8Cyclophosphamide 8camrelizumab 7Vincristine 5Dactinomycin 5toripalimab 3Trabectedin 3Radiation Dose Hypofractionation 3Etoposide 3Docetaxel 3ribociclib 2brostallicin 2Topotecan 2Thalidomide 2Temozolomide 2Sorafenib 2Oncolytic Virotherapy 2Nivolumab 2Neoadjuvant Therapy 2Melphalan 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ipilimumab 2Immune Checkpoint Inhibitors 2Gene Expression Profiling 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Sarcoma × Immune Checkpoint Inhibitors × Clear all
NCT04606108 2020-10-28

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Sun Yat-sen University

Phase 2 Unknown
62 enrolled
Sarcoma

Sarcoma

NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Hunan Cancer Hospital

Phase 2 Unknown
120 enrolled
GynecologicSarcoma

Sarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡